Lyra Therapeutics, Inc. — Director's Dealing 2021

Feb 10, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Lyra Therapeutics, Inc. (LYRA)
CIK: 0001327273
Period of Report: 2021-02-08

Reporting Person: Richard Robert E. (SVP of R&D)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-02-08	Stock Option	$10.63	A	18000	Acquired	2031-02-07	Common Stock (18000)	Direct

Footnotes

F1: This option vests and becomes exercisable in 48 equal monthly installments occurring on the completion of each successive month of the Reporting Person's service to the Issuer following February 8, 2021.